1-[1-[1-(2-methylbenzoyl)piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one | 634616-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[1-[1-(2-methylbenzoyl)piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 3-[1-[1-(2-methylbenzoyl)piperidin-4-yl]piperidin-4-yl]-1H-benzimidazol-2-one
• CAS: 634616-86-7
• 化学式: C₂₅H₃₀N₄O₂
• 分子量: 418.539
• InChiKey: NRZIRCFWEUKUBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(2-甲基苯甲酰基)哌啶-4-酮 、 4-（2-酮酸-1-苯并咪唑）哌啶 在 polymer-supported triacetoxyborohydride 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 1-[1-[1-(2-methylbenzoyl)piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  参考文献：
  名称：

  M1变构激动剂TBPB的类似物的合成和SAR。第二部分：酰胺，磺酰胺和脲类-封端远端碱性哌啶氮的作用。

  摘要：

  这封信描述了通过迭代类似物文库方法开发的高度选择性的M1变构激动剂TBPB类似物的进一步合成和SAR，该合成物是通过形成酰胺，磺酰胺和尿素来缺失远端碱性哌啶氮。尽管基本性和拓扑结构发生了很大变化，但仍保持了M1选择性。

  DOI：

  10.1016/j.bmcl.2008.09.032

文献信息

• Ophthalmic compositions for treating ocular hypertension
  申请人：Ogidigben J Miller

  公开号：US20050176765A1

  公开（公告）日：2005-08-11

  This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.

  本发明涉及选择性m1肌动蛋白受体激动剂，它们的使用或制剂在治疗青光眼和/或与患者眼内压力升高有关的其他疾病方面。本发明还涉及使用这些化合物为哺乳动物，特别是人类的眼提供神经保护作用。此外，本发明还涉及使用这些化合物治疗痴呆症，如阿尔茨海默病和血管性痴呆，抑郁症，注意力缺陷障碍，睡眠障碍，精神分裂症，疼痛，缺血，萎缩性胃炎和胃肠道无力。
• EP1515722A4
  申请人：——

  公开号：EP1515722A4

  公开（公告）日：2006-06-21
• OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION
  申请人：Merck & Co., Inc.

  公开号：EP1515722A2

  公开（公告）日：2005-03-23
• US7279490B2
  申请人：——

  公开号：US7279490B2

  公开（公告）日：2007-10-09
• [EN] OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION<br/>[FR] COMPOSITIONS OPHTALMIQUES DESTINEES A TRAITER L'HYPERTENSION OCULAIRE
  申请人：MERCK & CO INC

  公开号：WO2003105781A2

  公开（公告）日：2003-12-24

  This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.